Swiss multinational healthcare company pioneering pharmaceuticals and diagnostics with focus on oncology, immunology, and infectious diseases.
Profile & Fundamentals
Roche Holding: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Roche Holding Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Company profile record
Roche Holding AG
Common Stock · Health Care · Pharmaceuticals
Company
- Company / asset
- Roche Holding AG
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Pharmaceuticals
- HQ
- 🇨🇭 Switzerland
- Head office
- Grenzacherstrasse 124, Basel, Switzerland, 4070
Leadership & scale
- Chief executive
- Dr. Thomas Schinecker
- CEO year born
- 1975
- Full-time employees
- 103.2K
- Fiscal year end
- December
Fundamentals snapshot
- Market Cap
- CHF 283.1B
- P/E
- 13.0x
- Revenue (Q2 26)
- CHF 30.4B
- Profit (Q2 26)
- CHF 6.9B
- Dividend Yield
- 1.8%
- Revenue (FY 25)
- CHF 61.5B
- Shares in public float
- 654M
- Insider ownership
- 0%
Reporting & identifiers
- Symbol
- ROG.SIX
- Listing
- 🇨🇭 Switzerland | Dividend Tax: 35%
- Ticker Currency
- CHF
- Income Statement Currency
- CHF
- Balance Sheet Currency
- CHF
- Cash Flow Currency
- CHF
- EPS Currency
- CHF
- Contract Type
- SPOT
- ISIN
- CH0012032048
- Asset ID
- equity_73fd14fb-d2e2-59fd-a5e4-45499d17e077
Ownership
Shares Outstanding
Latest: 809.3M | Max: 865.8M | Min: 799.2M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
80.81%
654.0M latest reported shares
Insider Ownership
0.00%
Latest reported insider stake
Short Float
--
Latest reported short interest / float
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 860,000,000 |
| 2018-01-01 | 861,000,000 |
| 2019-01-01 | 865,772,700 |
| 2020-01-01 | 863,703,900 |
| 2021-01-01 | 857,465,900 |
| 2022-01-01 | 799,180,700 |
| 2023-01-01 | 804,000,000 |
| 2024-01-01 | 802,000,000 |
| 2025-01-01 | 803,000,000 |
| 2026-01-01 | 809,257,000 |
Top Holders
Available reported ownership records.
No reported records are available in this preview.
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
The headline earnings story seems confusing at first glance because reported Swiss franc revenues slipped while operating profits climbed. For fiscal 2025, reported sales edged down one percent to 61.5 billion Swiss francs, yet constant-currency sales expanded seven percent. Net profit rebounded sharply to 12.9 billion francs as prior-year write-downs faded. This performance shows that the underlying commercial engine is fundamentally sound. Rapid volume gains from newer blockbusters easily offset generic competition on older cancer therapies. Over fourteen billion francs in annual free cash flow proves that the business continues to generate high-quality, recurring cash.
The headline earnings story seems confusing at first glance because reported Swiss franc revenues slipped while operating profits climbed. For fiscal 2025, reported sales edged down one percent to 61.5 billion Swiss francs, yet constant-currency sales expanded seven percent. Net profit rebounded sharply to 12.9 billion francs as prior-year write-downs faded. This performance shows that the underlying commercial engine is fundamentally sound. Rapid volume gains from newer blockbusters easily offset generic competition on older cancer therapies. Over fourteen billion francs in annual free cash flow proves that the business continues to generate high-quality, recurring cash.
Revenue, Net Income, and Free Cash Flow
Latest: CHF 61.5B | Max: CHF 65.8B | Min: CHF 8.3B
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 12x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profit margins demonstrated impressive resilience in 2025 as the company successfully transitioned away from post-pandemic disruptions. Gross margins held remarkably firm near seventy-four percent, proving that customer demand for proprietary specialty medicines remains insensitive to broader inflation. Operating margin rebounded sharply to thirty-one percent as temporary restructuring costs and inventory charges ended. Favorable product mix shifts toward premium specialty medicines and high-margin diagnostic reagents provide structural operating leverage. This dual-engine business model successfully defends company profitability against mandatory government pricing reforms and generic biosimilar competition.
Profit margins demonstrated impressive resilience in 2025 as the company successfully transitioned away from post-pandemic disruptions. Gross margins held remarkably firm near seventy-four percent, proving that customer demand for proprietary specialty medicines remains insensitive to broader inflation. Operating margin rebounded sharply to thirty-one percent as temporary restructuring costs and inventory charges ended. Favorable product mix shifts toward premium specialty medicines and high-margin diagnostic reagents provide structural operating leverage. This dual-engine business model successfully defends company profitability against mandatory government pricing reforms and generic biosimilar competition.
Profitability Margins
Latest: 73.5% | Max: 73.9% | Min: 13.3%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
73.5%
Gross profit / revenue
Operating Margin
31.3%
Operating income / revenue
Net Margin
20.9%
Net income / revenue
FCF Margin
22.9%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 51,603,921,568.63 | 9,388,235,294.12 | 10,644,117,647.06 |
| 2017-12-31 | 57,234,086,242.3 | 8,863,449,691.99 | 14,902,464,065.71 |
| 2018-12-31 | 60,587,576,374.75 | 10,692,464,358.45 | 16,228,105,906.31 |
| 2019-12-31 | 65,858,471,074.38 | 13,943,181,818.18 | 19,506,198,347.11 |
| 2020-12-31 | 65,901,694,915.25 | 16,152,542,372.88 | 12,960,451,977.4 |
| 2021-12-31 | 68,860,745,614.04 | 15,274,122,807.02 | 17,565,789,473.68 |
| 2022-12-31 | 71,150,270,270.27 | 13,428,108,108.11 | 14,419,459,459.46 |
| 2023-12-31 | 71,782,660,332.54 | 13,655,581,947.74 | 13,593,824,228.03 |
| 2024-12-31 | 68,792,723,263.51 | 9,125,689,084.9 | 16,631,753,031.97 |
| 2025-12-31 | 77,573,770,491.8 | 16,242,118,537.2 | 17,757,881,462.8 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 12.46 | Trailing four quarters |
| 2024-12-31 | 10.36 | Trailing four quarters |
| 2023-12-31 | 8.22 | Trailing four quarters |
| 2022-12-31 | 18.69 | Annual net income |
| 2021-12-31 | 23.34 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 71.35 | 32.01 | 18.19 | 20.63 |
| 2017-12-31 | 71.5 | 31.03 | 15.49 | 26.04 |
| 2018-12-31 | 72.23 | 31.8 | 17.65 | 26.78 |
| 2019-12-31 | 72.73 | 32.99 | 21.17 | 29.62 |
| 2020-12-31 | 71.96 | 30.4 | 24.51 | 19.67 |
| 2021-12-31 | 68.63 | 28.91 | 22.18 | 25.51 |
| 2022-12-31 | 72.74 | 26.55 | 18.87 | 20.27 |
| 2023-12-31 | 72.94 | 25.47 | 19.02 | 18.94 |
| 2024-12-31 | 73.9 | 21.5 | 13.27 | 24.18 |
| 2025-12-31 | 73.53 | 31.32 | 20.94 | 22.89 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-08-13.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.